BTRX 246040

Drug Profile

BTRX 246040

Alternative Names: BTRX-246040; LY 2940094

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer BlackThorn Therapeutics; Eli Lilly
  • Class Antidepressants; Antiparkinsonians; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Nociceptin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Preclinical Parkinson's disease
  • Discontinued Alcoholism

Most Recent Events

  • 12 Dec 2017 9228737: Updated KDM, added PD and TT data, made neurological disorder line dormant as it is broad indication and details of specific dev lines are available. Creatd FET. Created relevant HEs. Sent THES request to map Antiparkionsonians as DC. Did not complete earlier FET as it talks about series of pII trials.
  • 07 Dec 2017 BlackThorn Therapeutics plans to initiate a phase IIa trial Parkinson’s disease in 2018
  • 07 Dec 2017 Preclinical trials in Parkinson's disease in USA (unspecified route) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top